Joseph C. Papa

Last updated

Joseph C. Papa
Born (1955-10-01) October 1, 1955 (age 68)
Connecticut, US
Alma mater University of Connecticut
Northwestern University
TitleChairman and CEO, Emergent BioSolutions
TermFeb 2024-
Board member ofEmergent BioSolutions
Children3

Joseph C. Papa (born October 1, 1955) is an American businessman and the chairman and chief executive officer (CEO) of Bausch & Lomb, a company formed from the initial public offering (IPO) of the eye health business of Bausch Health Companies Inc. [1]

Contents

Early life

Papa received a bachelor's degree in pharmacy from the University of Connecticut in 1978, and an MBA degree in marketing and finance from Northwestern University's Kellogg Graduate School of Management in 1983. [2]

Career

Papa has been chairman and CEO of Bausch & Lomb since its IPO in May 2022. [3] He was previously chairman and CEO of Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals International, Inc.), having succeeded J. Michael Pearson in those roles in May 2016. [4] Papa resigned as CEO of Bausch Health upon becoming chairman and CEO of Bausch & Lomb in May 2022, but retained his position as chairman of Bausch Health until his resignation on June 23, 2022. [5] Prior to joining Valeant, Papa was the chairman and CEO of Perrigo, an American manufacturer of private label over-the-counter pharmaceuticals, from 2006 to 2016. [6] From December 2004 to October 2006, Papa was chairman and CEO of the pharmaceutical and technologies services of Cardinal Health, an Ohio health care services company. From 2001 to 2004, he was president and chief operating officer of Watson Pharmaceuticals, Inc. He has also worked at Novartis and Pharmacia/Searle, where he launched the medications Celebrex, Diovan, and Lotrel. [7]

In 2014, he was ranked 47th on Harvard Business Review's "Best Performing CEOs in the World". [8]

Total compensation

In March 2017, it was reported that Papa received US$62.7 million in total compensation for his first eight months of work in 2016. [9] [10]

In March 2020, Bausch Health reported that Papa's gross income for 2019 rose to $17.1 million from $14.7 million in 2018. [11]

In May 2022, Bausch Health reported that Papa’s gross income increased again to $22.9 million, as compared to the $44,617 median compensation of all other Bausch Health employees, reflecting a pay ratio of 513:1. [12]

Personal life

As of May 2015, Papa had been married for 32 years. [13]

Related Research Articles

<span class="mw-page-title-main">Bausch & Lomb</span> American-Canadian eye health company

Bausch & Lomb is an American-Canadian eye health products company based in Vaughan, Ontario, Canada. It is one of the world's largest suppliers of contact lenses, lens care products, pharmaceuticals, intraocular lenses, and other eye surgery products. The company was founded in Rochester, New York, in 1853 by optician John Bausch and cabinet maker turned financial backer Henry Lomb. Until its sale in 2013, Bausch + Lomb was one of the oldest continually operating companies in the United States.

Bausch Health Companies Inc. is an American-Canadian multinational specialty pharmaceutical company based in Laval, Quebec, Canada. It develops, manufactures and markets pharmaceutical products and branded generic drugs, primarily for skin diseases, gastrointestinal disorders, eye health and neurology. Bausch Health owns Bausch & Lomb, a supplier of eye health products. Bausch Health's business model is primarily focused on acquiring small pharmaceutical companies and then sharply increasing the prices of the drugs these companies sell.

Mylan N.V. was a global generic and specialty pharmaceuticals company. In November 2020, Mylan merged with Upjohn, Pfizer's off-patent medicine division, to form Viatris. Previously, the company was domiciled in the Netherlands, with principal executive offices in Hatfield, Hertfordshire, UK and a "Global Center" in Canonsburg, Pennsylvania, US.

<span class="mw-page-title-main">Perrigo</span> Irish tax-registered pharmaceutical

Perrigo Company plc is an American Irish–registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters in Grand Rapids, Michigan, within Michigan State University's Grand Rapids Innovation Park.

<span class="mw-page-title-main">Allergan, Inc.</span> Former American conglomerate

Allergan, Inc. was an American global pharmaceutical company focused on eye care, neurosciences, medical dermatology, medical aesthetics, breast enhancement, obesity intervention and urologics. Allergan, Inc. was formed in 1948, incorporated in 1950 and became a public company in 1970. It ceased operation in 2015 when it was acquired by Irish-based Actavis plc, who then renamed the group as Allergan plc.

<span class="mw-page-title-main">Teva Pharmaceuticals</span> Israeli pharmaceutical company

Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. It specializes primarily in generic drugs, but other business interests include active pharmaceutical ingredients and, to a lesser extent, proprietary pharmaceuticals. Teva Pharmaceuticals was the largest generic drug manufacturer, when it was surpassed briefly by US-based Pfizer. Teva regained its market leader position once Pfizer spun off its generic drug division in a merger with Mylan, forming the new company Viatris at the end of 2020. Overall, Teva is the 18th largest pharmaceutical company in the world.

Fred Hassan, is a Pakistan-born American business executive who works for Warburg Pincus and was CEO of three global pharmaceutical companies.

<span class="mw-page-title-main">Bill Ackman</span> American billionaire hedge fund manager

William Albert Ackman is an American billionaire hedge fund manager who is the founder and chief executive officer of Pershing Square Capital Management, a hedge fund management company. His investment approach has made him an activist investor. As of January 2024, Ackman's net worth was estimated at $4 billion by Forbes.

<span class="mw-page-title-main">Medicis Pharmaceutical</span> Medical cosmetics company

Medicis Pharmaceutical is a medical cosmetics company based in Bridgewater, New Jersey. It is a subsidiary of Valeant Pharmaceuticals, which acquired the company in 2012. Medicis is known for products such as Solodyn and Ziana for treating acne, and for Restylane and Dysport for treating facial wrinkles.

William C. Weldon is a former chairman of Johnson & Johnson, He was the eighth chairman in Johnson & Johnson's history of more than one hundred years.

<span class="mw-page-title-main">Bepotastine</span> Chemical compound

Bepotastine is a 2nd generation antihistamine. It was approved in Japan for use in the treatment of allergic rhinitis and urticaria/pruritus in July 2000, and January 2002, respectively. It is marketed in the United States as an eye drop under the brand name Bepreve, by ISTA Pharmaceuticals, a subsidiary of Bausch + Lomb.

<span class="mw-page-title-main">ISTA Pharmaceuticals</span> US-based pharmaceutical company

ISTA Pharmaceuticals, Inc, was a US-based pharmaceutical company that specialized in ophthalmic pharmaceutical products and discovers, develops, and markets therapies for inflammation, ocular pain, glaucoma, allergy, and dry eye. ISTA was acquired by Bausch & Lomb, an eye care company, on March 26, 2012. Under the deal, Bausch & Lomb have agreed to pay $9.10 per share for ISTA, bringing the total value of the acquisition to $500 million. In 2012, Valeant Pharmaceuticals withdrew its $360 million offer.

<span class="mw-page-title-main">J. Michael Pearson</span>

J. Michael Pearson is a Canadian American pharmaceutical company executive. He is the former chairman and CEO of Valeant Pharmaceuticals International after being ousted in the aftermath of a report on pharmaceutical pricing published by Citron Research in April 2016.

Andrew Edward Left is an activist, short seller, author and editor of the online investment newsletter Citron Research, formerly StockLemon.com. Under the name Citron Research, Left publishes reports on firms that he claims are overvalued or are engaged in fraud. Left is known for advising investors on short selling and has often appeared on various media outlets such as CNBC and Bloomberg to talk about his opinions on stocks. In 2017, Left was called 'The Bounty Hunter of Wall Street' by The New York Times. Left gained further notoriety following his announced short of GameStop, precipitating a short squeeze that has hurt him and other short sellers in the short term.

David Edmund Ian Pyott CBE was the CEO of Allergan, a pharmaceutical company from 1998 to 2015, when Allergan was acquired by Actavis. In 2014 he was one of the 25 highest-paid CEOs in the United States.

Diplomat Pharmacy, Inc. is the largest independent provider of specialty pharmacy services in the United States. The company partners with manufacturers, payers, providers, hospitals, and more. Headquartered in Flint, Michigan, Diplomat has facilities across the United States and dispenses drugs in all 50 states. Diplomat offers specialized medication and medication management programs for patients with complex and chronic conditions such as cancer, hepatitis, multiple sclerosis, HIV and others.

John T. Hendrickson is an American businessman, the chairman, president and chief executive officer (CEO) of Perrigo, since April 2016, when he succeeded Joseph C. Papa, who became the chairman and CEO of Valeant Pharmaceuticals.

Knight Therapeutics Inc. is a Canadian public specialty pharmaceutical company based in Montreal, Quebec that focuses on acquiring or in-licensing innovative pharmaceutical products for the Canadian and select international markets. It is listed on the Toronto Stock Exchange, with a market capitalization of $1.02 billion as of August 2019.

Brent Saunders is an American biopharma executive and entrepreneur who is the chairman and CEO of the health company Bausch & Lomb. He helped lead various mergers and acquisitions, including the mergers between Merck and Schering-Plough, the acquisition of Bausch + Lomb by Valeant Pharmaceuticals, and the $63 billion acquisition of Allergan by Abbvie. He is the founder of special-purpose acquisition company (SPAC) Vesper Healthcare Acquisition. Saunders is also executive chairman of medical aesthetics companies The Beauty Health Company and Hugel America.

References

  1. Inc, Bausch + Lomb Corporation; Bausch Health Companies. "Bausch + Lomb Corporation Announces Pricing of IPO". www.prnewswire.com (Press release). Retrieved June 24, 2022.{{cite press release}}: |last= has generic name (help)CS1 maint: multiple names: authors list (link)
  2. "#161 Joseph C Papa". Forbes . Archived from the original on June 1, 2012. Retrieved May 10, 2016.
  3. "Bausch + Lomb Up in Debut After Below-Range $630 Million IPO". Bloomberg.com. May 6, 2022. Retrieved June 24, 2022.
  4. Gara, Antoine. "Former Perrigo CEO Joe Papa Will Replace Michael Pearson At Valeant Pharmaceuticals". Forbes. Retrieved June 24, 2022.
  5. Kilgore, Tomi. "Bausch Health's Joe Papa resigns from board, John Paulson named chairperson". MarketWatch. Retrieved June 24, 2022.
  6. "Valeant new ceo pay package - Business Insider". Uk.businessinsider.com. March 31, 2016. Retrieved April 29, 2016.
  7. "Valeant Names Joseph C. Papa To Be Chairman And Chief Executive Officer Of Valeant Pharmaceuticals". ir.valeant.com/. Valeant Pharmaceuticals International, Inc. April 25, 2016. Retrieved May 10, 2016.
  8. Staff, Harvard Business Review (November 1, 2014). "The Best-Performing CEOs in the World". Harvard Business Review. No. November 2014. ISSN   0017-8012 . Retrieved February 26, 2020.{{cite news}}: |first= has generic name (help)
  9. "Valeant paid CEO Joe Papa US$63M in compensation for eight months of work — but mostly in company stock | Financial Post". Business.financialpost.com. Retrieved June 19, 2017.
  10. "New Valeant Pharmaceuticals CEO compensated US$63-million in 2016".
  11. "BRIEF-Bausch Health Reports CEO Joseph C. Papa's 2019 Total Compensation Was $17.1 Mln". Reuters. March 17, 2020. Retrieved June 9, 2020.
  12. "DEF 14A". www.sec.gov. Retrieved June 24, 2022.
  13. "Perrigo's Joe Papa says shareholders, Allegan truly different". mlive.com. November 14, 2015. Retrieved October 3, 2018.